Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

LENSAR, Inc. Common Stock

LNSR

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.

Last trade $5.18
Day change -$0.11 (-2.08%)
Day range $5.17 – $5.40
Volume 88,497
Market cap $65M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$65.04M
Price / earnings
4.19×
Price / book
4.36×
Price / sales
1.08×
EV / sales
0.92×
EV / EBITDA
-15.53×

Profitability

Earnings per share
$1.26
Return on assets
22.3%
Return on equity
104.06%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.25×
Current ratio
2.39×
Quick ratio
1.13×
Cash ratio
0.69×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.33M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LNSR, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$16.5M$13.43M$16.03M$14.32M$13.94M$14.16M$16.73M$13.54M
Cost of revenue$6.72M$7.05M$9.09M$8.28M$6.91M$7.03M$9.62M$7.27M
Gross profit$9.78M$6.38M$6.94M$6.04M$7.02M$7.13M$7.11M$6.27M
Selling, general and administrative$6.14M$2.53M$10.33M$12.02M$11.66M$11.15M$6.83M$6.08M
Research and development$1.27M$1.39M$1.3M$1.37M$1.43M$1.53M$1.34M$1.2M
Total operating expenses$7.64M$4.14M$11.86M$13.62M$13.31M$12.92M$8.4M$7.51M
Operating income$2.13M$2.24M-$4.92M-$7.58M-$6.29M-$5.79M-$1.29M-$1.25M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$3.54M$36.33M-$1.46M-$3.71M-$1.76M-$27.35M-$18.7M-$1.5M
Income taxes$0$0$0$0$0$0$0$0
Net income$3.54M$36.33M-$1.46M-$3.71M-$1.76M-$27.35M-$18.7M-$1.5M
Net income attributable to common shareholders$1.77M$18.91M-$1.46M-$3.71M-$1.76M-$27.35M-$18.7M-$1.5M
EBITDA$3.24M$3.37M-$3.75M-$6.42M-$5.19M-$4.71M-$184K-$239K
Basic earnings per share$0.14$1.56-$0.12-$0.31-$0.15-$2.32-$1.61-$0.13
Diluted earnings per share$0.10$0.00-$0.12-$0.31-$0.15-$2.32-$1.61-$0.13

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review

Alcon has terminated its merger agreement with LENSAR, a laser solutions company, after prolonged regulatory review by the Federal Trade Commission made the deal unattractive. The acquisition, originally agreed upon in March 2025 at $14.00 per share, faced extended delays and opposition. LENSAR shares plunged 25.44% in premarket trading to $7.65, hitting a new 52-week low.

Benzinga

LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC

LENSAR, Inc. announced the termination of its merger agreement with Alcon Research, LLC due to FTC opposition. The companies mutually agreed that obtaining necessary U.S. regulatory approvals was unlikely by the merger's outside date. LENSAR will retain the $10.0 million deposit and plans to focus on expanding its ALLY Robotic Cataract Laser System globally. Financial results and go-forward strategy details will be shared on March 31, 2026.

GlobeNewswire Inc.

LENSAR® Provides Update on Pending Acquisition by Alcon

LENSAR, Inc. announced that its pending acquisition by Alcon Research, LLC remains under FTC review following a Second Request for Additional Information. The company expects to close the transaction in the first half of 2026, subject to regulatory approval and satisfaction of closing conditions.

GlobeNewswire Inc.

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

SpyGlass Pharma announced the appointment of Elizabeth O'Farrell to its Board of Directors, bringing over 30 years of healthcare industry experience. She will serve as an Independent Director and Chair of the Audit Committee, supporting the company's advancement of its Drug Delivery Platform for glaucoma management.

GlobeNewswire Inc.

LENSAR Reports Second Quarter 2025 Results and Provides Business Update

LENSAR reported strong Q2 2025 performance with 18 ALLY Robotic Cataract Laser Systems placed, 23% increase in worldwide procedure volumes, and continued progress on its proposed merger with Alcon. Total revenue increased 10% to $13.9 million, with net loss improving to $1.8 million.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.